Galapagos NV

459 articles with Galapagos NV

• 

  Galapagos and MorphoSys Ink Deal with Novartis for $1.111 Billion+

  7/19/2018

  Galapagos and MorphoSys signed an exclusive development and commercialization deal with Swiss-based Novartis.
• 

  Is Gilead Poised for a Comeback?

  7/6/2018

  Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.
• 

  Galapagos Plunges Following Mixed CF Trial Results and AbbVie Decision to Walk Away From Collabor...

  6/29/2018

  Shares of Galapagos NV fell more than 15 percent Thursday afternoon and continued to fall in premarket trading after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration.
• 

  Primary Endpoint Hit: Gilead and Galapagos’ JAK1 Inhibitor for Arthritis Positive in Phase II

  5/31/2018

  Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.

• Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis

  5/30/2018

  Gilead Sciences, Inc. and Galapagos NV announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16.

• Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

  5/2/2018

  Galapagos NV and MorphoSys AG announced today that the first patient has been screened in IGUANA, a Phase 2 study with MOR106.

• Galapagos presents strong disease-modifying effects in preclinical model of osteoarthritis with GLPG1972 at OARSI 2018

  4/29/2018

  Galapagos NV presents preclinical results showing broad beneficial effects on cartilage and bone with GLPG1972 in an osteoarthritis (OA) rat model at the Osteoarthritis Research Society International (OARSI) World Congress today in Liverpool, UK.

• 

  Eli Lilly and Incyte Shares Drop as FDA Raises Concerns about Arthritis Drug

  4/19/2018

  Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.

• ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer technology

  1/8/2018

  The targets that will be pursued in the collaboration and financial details about the collaboration are not disclosed.

• Galapagos Release: Positive Topline Results With GLPG1972 in Osteoarthritis Patients

  1/8/2018

  Galapagos evaluated GLPG1972 in a randomized, placebo-controlled, double-blind Phase 1b study in 30 patients aged 50 to 75 years with diagnosis of knee and/or hip osteoarthritis, in the United States.

• Galapagos NV: Update on Progress in Cystic Fibrosis Programs

  1/3/2018

  The company provided an update on several aspects of its cystic fibrosis (CF) program.

• 

  Gilead Could Acquire Galapagos Within Weeks

  12/18/2017

  Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
• 

  In the Nick of Time: Galapagos Nabs Co-Promotion Filgotinib Deal With Gilead

  12/15/2017

  Galapagos assumes 35% of the co-promotion efforts in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, and Luxembourg.

• Galapagos: Transparency Notification - Dec. 12, 2017

  12/12/2017

  Galapagos received a transparency notification from Fidelity Management & Research LLC.

• Galapagos Release: Transparency Notification

  12/12/2017

  Pursuant to Belgian transparency legislation, Galapagos received a transparency notification on 7 December 2017 from FMR LLC.

• Galapagos to Enter NASDAQ Biotech Index

  12/11/2017

  The company will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017.

• Galapagos Increases Share Capital Through Warrant Exercises – Nov. 27, 2017

  11/27/2017

  Galapagos issued 41,000 new ordinary shares on 23 November 2017, for a total capital increase (including issuance premium) of €353,835.00.

• Galapagos NV: ALBATROSS With GLPG2222 Shows Positive Clinical Results in CF Patients

  11/20/2017

  The ALBATROSS study included 37 cystic fibrosis patients with a gating (Class III) mutation on one allele and F508del (Class II) mutation on the other allele.

• Galapagos: Consistent Safety Findings and Durable Activity With Filgotinib Treatment of Rheumatoid Arthritis Patients Up to Week 84 in DARWIN 3 Study

  11/6/2017

  Galapagos presents data from DARWIN 3, other filgotinib studies and Galapagos' GLPG1972 at American College of Rheumatology Meeting 2017.

• Galapagos Moving Forward in CF Programs at NACFC 2017

  11/2/2017

  Ten posters and four oral presentations reflect progress toward triple combination therapy.